Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Heparinex, Novo Nordisk deal

March 24, 2014 7:00 AM UTC

Heparinex's Caisson Biotech LLC subsidiary granted Novo Nordisk exclusive rights to commercialize insulin conjugated to HEPtune heparosan-based drug delivery technology and non-exclusive rights to use the technology for additional indications, including diabetes, human growth hormone therapy, obesity and inflammatory diseases. Under the deal, Caisson is eligible for up to $167 million in an undisclosed upfront payment and milestone payments, plus royalties. Under a 2012 deal worth up to $100 million, Novo has exclusive rights to use HEPtune technology to develop compounds within undisclosed indications (see BioCentury, May 7, 2012). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article